Global Obesity Treatment Market Faces Shake-Up
The expiration of a key patent on semaglutide—the active ingredient in blockbuster weight-loss drugs Ozempic and Wegovy has set the stage for a dramatic expansion of access to obesity treatments, with India’s generic pharmaceutical industry poised to flood the market with lower-cost alternatives that could fundamentally alter the economics of weight management worldwide.
The patent expired on March 20, 2026, in India, the world’s largest supplier of generic medicines, triggering what analysts describe as an aggressive new race among domestic drug manufacturers. At least four major Indian pharmaceutical firms have already prepared generic semaglutide injections, according to regulatory filings and compliance documents, with some announcing “Day 1” launches that could make cheaper versions available as soon as this weekend.
Research firm Pharmarack estimates the Indian market will soon be saturated with options. “What we understand is, there will be more than 50 brands that will be launched in the market and there are more than 40 players who will be launching these drugs,” Sheetal Sapale, vice president of Pharmarack, said.
The development arrives as global obesity rates continue their upward trajectory and follows years of surging demand for GLP-1 receptor agonists, a class of drugs that have demonstrated significant efficacy in weight reduction. By the end of 2026, core patents on semaglutide will have expired in 10 countries that collectively represent 48 percent of the global obesity burden, according to a study published earlier this month by researchers. These countries include Brazil, China, South Africa, Turkey, and Canada.
For patients and healthcare systems in middle-income countries, where weight-loss injections have long been considered luxury items accessible only to affluent populations, the arrival of generic versions represents a potential paradigm shift. In India, current branded versions of these drugs cost between 15,000 and 22,000 rupees ($161–$236) per month, a price point that effectively excludes the majority of the population.
Swati Pradhan, who runs a weight-loss clinic in Mumbai, expects patient numbers to rise substantially once generics push treatment costs closer to 5,000 rupees ($60) per month. At clinics across the city, doctors report already seeing high levels of interest that existing price barriers have suppressed.
“We have around 70 to 80 patients on active treatment right now,” Nadeem Rais, an endocrinologist in Mumbai, said. “When generics come out and prices drop, that could go up to 200 easily.”
His colleague Sunera Ghai described demand as “very high” but noted that many potential patients “probably aren’t taking it just because it is truly a luxury item at this point.”
The economic barriers to treatment have forced some patients to abandon therapy midway. Sukant Mangal, a 46-year-old patient who lost nearly 30 pounds over eight months on the medication, observed that many people he knows discontinued treatment after realising they would need to spend 20,000 rupees ($214) monthly for seven to eight months. “Had it been cheaper, (it) would’ve been much easier to have it,” he said.
The timing of the patent expiration coincides with significant shifts in India’s health landscape. While the country still accounts for one-third of the world’s undernutrition according to the World Health Organisation, rising incomes and increasingly urban lifestyles have driven obesity rates sharply upward. Government data released in March 2025 shows that 24 percent of women and 23 percent of men in India are now classified as overweight or obese.
Bariatric surgeon Sanjay Borude noted a distinctive pattern in how economic status correlates with physical activity in India, contrasting with trends observed in higher-income countries. “Once a person starts earning money, he becomes more sedentary here,” Borude said. “While in first-world countries, the more the money, they become more active and devote time for their health, this is reversed in India.”
This economic dynamic has proved highly profitable for multinational pharmaceutical companies. India’s weight-loss drug sales have grown tenfold over five years to $153 million as of 2026, and projections indicate the market could surpass half a billion dollars by 2030. Eli Lilly’s Mounjaro became the country’s top-selling drug by value last year, outperforming even common antibiotics.
The availability of generic semaglutide from Indian manufacturers carries implications that extend far beyond the country’s borders. India supplies more than half of Africa’s generic medicines, and cheaper versions of the drug could provide a critical intervention for regions where obesity rates are rising rapidly but treatment options remain prohibitively expensive.
Simon Barquera, president of the World Obesity Federation, noted that lower-cost semaglutide could significantly expand access to effective treatment, particularly in middle-income countries where price has been a major barrier. However, Barquera also emphasised that pharmaceutical interventions alone are insufficient to address the broader challenge.
“Medication alone will not reverse the global rise in obesity. Obesity is a complex, chronic disease,” Barquera said, highlighting the continued importance of prevention efforts and the creation of healthier environments.
Indian drug manufacturers are already positioning themselves for international markets. Dr Reddy’s Laboratories has announced plans to launch its version of semaglutide in Canada by May 2026, signalling the beginning of a broader global expansion of generic competition.
Healthcare professionals caution that while expanded access to these medications offers significant public health opportunities, patients and providers must remain mindful of potential side effects. Use of GLP-1 receptor agonists can cause adverse reactions including nausea and gastrointestinal issues, and medical supervision is recommended for those initiating treatment.
The availability of multiple generic versions from various manufacturers also raises considerations around quality control and regulatory oversight, areas where India’s pharmaceutical industry has faced scrutiny in the past. The country’s drug regulatory authorities are expected to maintain monitoring protocols as new products enter the market.
As generic versions become available, the landscape of obesity treatment is set for a period of rapid transformation. For millions of individuals who have been unable to afford existing options, the next weeks and months may mark the beginning of access to treatments previously reserved for the wealthiest segments of society.